CITYSCAPE: Tiragolumab plus atezolizumab for non-small cell lung cancer
Published: 17 Jun 2020
Views: 250
Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA
Dr Melissa Johnson speaks to ecancer in an online interview for the virtual ASCO 2020 meeting.
The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC.
Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study.
Related Videos
IMvigor130: Atezolizumab with or without chemotherapy in metastatic urothelial c...
Prof Matthew Galsky - The Mount Sinai Hospital, New York, USA
30 Jun 2020
Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLC
Prof Martin Reck - Lung Clinic Grosshansdorf, Grosshansdorf, Germany
30 Jun 2020
Checkpoint inhibitors for the treatment of advanced hepatocellular carcinoma
Dr Katie Kelley - University of California San Francisco, San Francisco, USA
12 Jun 2020
Brigatinib for NSCLC, latest research and overcoming complications
Dr Ross Camidge - University of Colorado Cancer Center, Aurora, USA
29 May 2020
PARP inhibitors for metastatic breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
7 Oct 2019
Targeted therapies in prostate cancer: Recent advances presented at ESMO 2019
Dr Eleni Efstathiou, Prof Noel Clarke, Dr Elena Castro, Prof Matthew Smith
30 Sep 2019
Latest data from KEYNOTE 42: Pembrolizumab vs chemotherapy in treatment-naive pa...
Prof Tony Mok - Chinese University of Hong Kong, Hong Kong
18 Apr 2019
ASCO GU 2019 renal highlights
Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA
14 Feb 2019
Landscape change with oral proteasome maintenance in multiple myeloma patients
Prof Maria-Victoria Mateos, Prof Wee Joo Chng, Prof Meral Beksac and Dr Sagar Lo...
3 Dec 2018
